NaV1.5-CARED
Financiado
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic...
NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death
The voltage-gated sodium channel (Na-channel; NaV1.5) is a central component of cardiac electrogenesis. Its dysfunction can lead to ventricular fibrillation and sudden cardiac death. While NaV1.5 represents a highly relevant thera...
The voltage-gated sodium channel (Na-channel; NaV1.5) is a central component of cardiac electrogenesis. Its dysfunction can lead to ventricular fibrillation and sudden cardiac death. While NaV1.5 represents a highly relevant therapeutic target for prevention of life-threatening cardiac arrhythmias, therapies that target the expression or function of this channel are non-existent. Such a therapy would provide for the first time an alternative for the invasive and costly cardioverter defibrillator or pacemaker therapies currently used. NaV1.5-CARED consortium proposes to capitalize on their largest worldwide cohorts of patients with inherited cardiac electrical and conduction defects to uncover regulatory regions and proteins that modulate NaV1.5 expression and function with the goal to develop and validate innovative therapies to restore the function of NaV1.5. We have three objectives: 1) predict the risk of (fatal) arrhythmia and conduction defect at the individual level by developing personalized polygenic risk score (PRS), 2) characterize the molecular mechanism associating regulatory DNA regions and genes with the cardiac diseases to uncover new therapeutic targets, 3) and develop new candidates for therapeutic intervention able to restore Nav1.5 loss of function. After databases harmonization, we will conduct whole genome genetic studies to identify variants associated with ventricular arrhythmia and conduction defects and generate PRS relevant to stratify the risk of arrhythmia and degree of conduction defect. Genetic studies will also be used to identify new therapeutic that will be evaluated in dedicated and high-throughput human cardiomyocytes derived induced pluripotent cell models.
ver más
Duración del proyecto: 63 meses
Fecha Inicio: 2023-06-21
Fecha Fin: 2028-09-30
Fecha Fin: 2028-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-21
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
5M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
937.50K€ |
Participante
383.75K€ |
Participante